The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Open accessAbstract
Heterozygous mutations in the gene encoding isocitrate dehydrogenase-1 ( IDH1 ) occur in certain human brain tumors, but their mechanistic role in tumor development is unknown. We have shown that tumor-derived IDH1 mutations impair the enzyme's affinity for its substrate and dominantly inhibit wild-type IDH1 activity through the formation of catalytically inactive heterodimers. Forced expression of mutant IDH1 in cultured cells reduces formation of the enzyme product, α-ketoglutarate (α-KG), and increases the levels of hypoxia-inducible factor subunit HIF-1α, a transcription factor that facilitates tumor growth when oxygen is low and whose stability is regulated by α-KG. The rise in HIF-1α levels was reversible by an α-KG derivative. HIF-1α levels were higher in human gliomas harboring an IDH1 mutation than in tumors without a mutation. Thus, IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HIF is stabilized in IDH-associated gliomas; this has been proposed to be a consequence of intracellular depletion of 2OG following IDH loss of function (Zhao et al, 2009).”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Zhao et al, 2009
In the citing paper
“The IDH mutations occur at substrate-binding arginine residues (Arg 132 in IDH1; Arg 140 and Arg 172 in IDH2) and inactivate IDH for conversion of isocitrate to 2-oxoglutarate (2OG; Zhao et al, 2009).”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Zhao et al, 2009
In the citing paper
“Overexpression of IDH1 Arg 132 mutants results in elevated HIFa levels (Zhao et al, 2009).”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Zhao et al, 2009
In the citing paper
“The stability of HIF‐1α is regulated by α‐KG, and increasing α‐KG reduces the expression of HIF‐1α.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [168]
In the citing paper
“Inhibiting the mitochondrial enzyme SDH during ischaemia by preloading tissues with the SDH inhibitor DMM prevented succinate accumulation during ischaemia and protected against tissue damage upon reperfusion150.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [150]
In the citing paper
“succinate accumulated during ischaemia and is then oxidised upon reperfusion to drive the mitochondrial superoxide formation that contributes to ischaemia-reperfusion (IR) injury150,151.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [150]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
Xu, X., Zhao, J., Xu, Z., Peng, B., Huang, Q., Arnold, E., & Ding, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404298200 · Cited by 407
Self-citationBleeker, F. E., Lamba, S., Leenstra, S., Troost, D., Hulsebos, T. J. M., Vandertop, W. P., Frattini, M., Molinari, F., Knowles, M. A., Cerrato, A., et al. (2009) · Human Mutation · doi:10.1002/humu.20937 · Cited by 365
Evaluation of HIF-1 inhibitors as anticancer agents
Semenza, G. L. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.006 · Cited by 363
MacKenzie, E. D., Selak, M. A., Tennant, D. A., Payne, L. J., Crosby, S., Frederiksen, C. M., Watson, D. G., & Gottlieb, E. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01927-06 · Cited by 359
Cellular concentrations of enzymes and their substrates
Albe, K. R., Butler, M. H., & Wright, B. E. (1990) · Journal of Theoretical Biology · doi:10.1016/s0022-5193(05)80266-8 · Cited by 318
Multiple NADPH-producing pathways control glutathione (GSH) content in retina
Winkler, B. S., Desantis, N. M., & Solomon, F. (1986) · Experimental Eye Research · doi:10.1016/s0014-4835(86)80013-6 · Cited by 107
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 999
Metabolism Shapes Immune Responses to Staphylococcus aureus
Arumugam, P., & Kielian, T. (2023) · Journal of Innate Immunity · doi:10.1159/000535482 · Cited by 39
Mitochondrial energy metabolism and apoptosis regulation in glioblastoma
Nagy, Á., Éder, K., Selak, M. A., & Kálmán, B. (2014) · Brain Research · doi:10.1016/j.brainres.2014.10.062 · Cited by 37
Chronic hypoxia leads to a glycolytic phenotype and suppressed HIF-2 signaling in PC12 cells
Zhdanov, A. V., Dmitriev, R. I., Golubeva, A. V., Gavrilova, S. A., & Papkovsky, D. B. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.02.016 · Cited by 35
Damm, F., Bunke, T., Thol, F. R., Markus, B., Wagner, K., Göhring, G., Schlegelberger, B., Heil, G., Reuter, C. W., Püellmann, K., et al. (2011) · Leukemia · doi:10.1038/leu.2011.200 · Cited by 37
Ratcliffe, P. J., Koivunen, P., Myllyharju, J., Ragoussis, J., Bovée, J. V. M. G., Batinic̈‐Haberle, I., Vinatier, C. S., Trichet, V., Robriquet, F., Oliver, L., et al. (2017) · Hypoxia · doi:10.2147/hp.s127042 · Cited by 35
Optical Analysis of Glioma: Fourier-Transform Infrared Spectroscopy Reveals the IDH1 Mutation Status
Uckermann, O., Juratli, T. A., Galli, R., Conde, M., Wiedemuth, R., Krex, D., Geiger, K. D., Temme, A., Schackert, G., Koch, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1795 · Cited by 36
Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations
Buege, M. J., DiPippo, A. J., & Dinardo, C. D. (2018) · Cancers · doi:10.3390/cancers10060187 · Cited by 35
The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
Liu, Y., Xu, W., Li, M., Yang, Y., Sun, D., Chen, L., Li, H., & Chen, L. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.019 · Cited by 37
Self-citationTCA cycle-derived oncometabolites in cancer and the immune microenvironment
Sarkar, S., Chang, C.-I., Jean, J., & Wu, M. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01186-y · Cited by 39
IDH1 mutations inhibit multiple α-ketoglutarate-dependent dioxygenase activities in astroglioma
Liu, Y., Jiang, W., Liu, J., Zhao, S., Xiong, J., Mao, Y. Q., & Wang, Y. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0914-4 · Cited by 37
Self-citationThe hypoxia signalling pathway in haematological malignancies
Irigoyen, M., García‐Ruiz, J. C., & Berra, E. (2017) · Oncotarget · doi:10.18632/oncotarget.15981 · Cited by 36
Liu, L., Li, T., Song, G., He, Q., Yin, Y., Lu, J. Y., Bi, X., Wang, K., Luo, S., Chen, Y., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz032 · Cited by 34
Li, Y., Qin, Q., Zhang, Y., & Cao, Y. (2022) · Current Oncology · doi:10.3390/curroncol29100542 · Cited by 34
Rapid detection of IDH mutations in gliomas by intraoperative mass spectrometry
Hua, W., Zhang, W., Brown, H. M., Wu, J., Fang, X., Shahi, M., Chen, R., Zhang, H., Jiao, B., Wang, N., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2318843121 · Cited by 36
Yao, Y., Chan, A. K., Qin, Z., Chen, L. C., Zhang, X., Pang, J. C., Li, H. M., Wang, Y., Mao, Y. Q., Ng, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067421 · Cited by 34
Take Advantage of Glutamine Anaplerosis, the Kernel of the Metabolic Rewiring in Malignant Gliomas
Martins, F., Gonçalves, L. G., Pojo, M., & Serpa, J. (2020) · Biomolecules · doi:10.3390/biom10101370 · Cited by 35
Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma
Minasi, S., Baldi, C., Gianno, F., Antonelli, M., Buccoliero, A. M., Pietsch, T., Massimino, M., & Buttarelli, F. R. (2020) · Child s Nervous System · doi:10.1007/s00381-020-04933-8 · Cited by 33
Yang, Y., Jin, X., Li, Q., Chen, Y., Chen, F., Zhang, H., Su, Y., Xiao, Y., Di, G., Jiang, Y., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2207201119 · Cited by 35
The expression and significance of IDH1 and p53 in osteosarcoma
Hu, X., Yu, A., Qi, B., Fu, T., Wu, G., Zhou, M., Luo, J., & Xu, J.-H. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-43 · Cited by 35
Jiang, B., Zhang, J., Xia, J., Zhao, W., Wu, Y., Shi, M., Luo, L., Zhou, H., Chen, A., Ma, H., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.053 · Cited by 33
Meng, D., Chen, Y., Yun, D., Zhao, Y., Wang, J., Xu, T., Li, X., Wang, Y., Li, Y., Sun, R., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3208 · Cited by 34
Neomorphic mutations create therapeutic challenges in cancer
Takiar, V., Ip, C. K. M., Gao, M., Mills, G. B., & Cheung, L. W. T. (2016) · Oncogene · doi:10.1038/onc.2016.312 · Cited by 33
Altered Mitochondrial Signalling and Metabolism in Cancer
Chattopadhyay, E., & Roy, B. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00043 · Cited by 36
Integration of hypoxic HIF-α signaling in blood cancers
Schito, L., Rey, S., & Konopleva, M. Y. (2017) · Oncogene · doi:10.1038/onc.2017.119 · Cited by 34
Han, L., Wang, S., Miao, Y., Shen, H., Guo, Y., Xie, L., Shang, Y., Dong, J., Li, X., Wang, W., et al. (2019) · European Journal of Radiology · doi:10.1016/j.ejrad.2019.01.025 · Cited by 33
Macklin, P. S., Yamamoto, A., Browning, L., Hofer, M., Adam, J., & Pugh, C. W. (2020) · The Journal of Pathology · doi:10.1002/path.5402 · Cited by 33
Popov, S., Jury, A., Laxton, R. C., Doey, L. J., Kandasamy, N., Al‐Sarraj, S., Jürgensmeier, J. M., & Jones, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056328 · Cited by 33
Verlingue, L., Hollebecque, A., Boige, V., Ducreux, M. P., Malka, D., & Ferté, C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.006 · Cited by 33
Niu, N., Ye, J., Hu, Z., Zhang, J., & Wang, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087076 · Cited by 34
The future of high-grade glioma: Where we are and where are we going
Chamberlain, M. C., Rhun, É. L., & Taillibert, S. (2015) · Surgical Neurology International · doi:10.4103/2152-7806.151331 · Cited by 34
Metabolic Regulation in Mitochondria and Drug Resistance
Pan, Y., Cao, M., Liu, J., Yang, Q. K., Miao, X., Go, V. L. W., Lee, P. W. N., & Xiao, G. G. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6674-0_11 · Cited by 33
The PHD1 oxygen sensor in health and disease
Kennel, K. B., Burmeister, J., Schneider, M. A., & Taylor, C. T. (2018) · The Journal of Physiology · doi:10.1113/jp275327 · Cited by 34
Rapid diagnosis of IDH1-mutated gliomas by 2-HG detection with gas chromatography mass spectrometry
Xu, H., Xia, Y., Li, C., Zhang, J., Liu, Y., Wei, Y., Qin, Z., Chen, L., Shi, Z., Quan, K., et al. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0163-z · Cited by 32
Self-citationHIF-Dependent Mechanisms of Relationship between Hypoxia Tolerance and Tumor Development
Dzhalilova, D. S., & Makarova, O. V. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921100011 · Cited by 34
IDH1 and IDH2 mutations in myeloid neoplasms - Novel paradigms and clinical implications
Cazzola, M. (2010) · Haematologica · doi:10.3324/haematol.2010.030015 · Cited by 32
Schlisio, S. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00881.x · Cited by 33
Small molecule KDM4s inhibitors as anti-cancer agents
Lin, H., Li, Q., Li, Q., Zhu, J., Gu, K. X., Jiang, X., Hu, Q., Feng, F., Qu, W., Chen, Y., et al. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1455676 · Cited by 32
Vageli, D. P., Doukas, P. G., Goupou, K., Benos, A. D., Astara, K., Zacharouli, K., Sotiriou, S., & Ιωάννου, Μ. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.052130 · Cited by 34
Epigenetic alterations and microRNAs
Vasilatou, D., Papageorgiou, S. G., Dimitriadis, G., & Pappa, V. (2013) · Epigenetics · doi:10.4161/epi.24897 · Cited by 33
Atai, N. A., Renkema-Mills, N. A., Bosman, J., Schmidt, N., Rijkeboer, D., Tigchelaar, W., Bosch, K. S., Troost, D., Jonker, A., Bleeker, F. E., et al. (2011) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155411400606 · Cited by 32
DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas
Paul, Y., Mondal, B., Patil, V. S., & Somasundaram, K. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0331-9 · Cited by 31
Clinical and immunological correlates of long term survival in glioblastoma
Czapski, B., Baluszek, S., Herold‐Mende, C. C., & Kaminska, B. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.73893 · Cited by 31
Chen, D., Xia, S., Wang, M., Lin, R., Li, Y., Mao, H. Z., Aguiar, M., Famulare, C. A., Shih, A. H., Brennan, C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1040 · Cited by 34
Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
Park, J., & Turcan, Ş. (2019) · Cancers · doi:10.3390/cancers11101616 · Cited by 33
Fujiwara, H., Tateishi, K., Misumi, K., Hayashi, A., Igarashi, K., Kato, H., Nakatsuka, T., Suzuki, N., Yamamoto, K., Kudo, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55211-w · Cited by 32
Crispo, F., Pietrafesa, M., Condelli, V., Maddalena, F., Bruno, G., Piscazzi, A., Sgambato, A., Esposito, F., & Landriscina, M. (2020) · Molecules · doi:10.3390/molecules25163754 · Cited by 32
Role of succinate dehydrogenase deficiency and oncometabolites in gastrointestinal stromal tumors
Zhao, Y., Feng, F., Guo, Q., Wang, Y., & Zhao, R. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i34.5074 · Cited by 35
IDH1 and IDH2 hotspot mutations are not found in canine glioma
Reitman, Z. J., Olby, N. J., Mariani, C. L., Thomas, R. J., Breen, M., Bigner, D. D., McLendon, R. E., & Yan, H. (2009) · International Journal of Cancer · doi:10.1002/ijc.25017 · Cited by 31
The future role of personalized medicine in the treatment of glioblastoma multiforme
Adamson, C. (2010) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s6852 · Cited by 32
Kim, B. Y. S., Jiang, W., Beiko, J., Prabhu, S. S., DeMonte, F., Gilbert, M. R., Sawaya, R. A., Aldape, K., Cahill, D. P., & McCutcheon, I. E. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1451-0 · Cited by 31
Self-citationKuo, C., Cheng, C.-T., Hou, P., Lin, Y.-P., Ma, H., Chung, Y., Chi, K. K., Chen, Y., Li, W., Kung, H.-J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8570 · Cited by 32
Self-citationMa, T., Peng, Y., Huang, W., & Ding, J. (2017) · Scientific Reports · doi:10.1038/srep40921 · Cited by 31
Self-citationCancer metabolomics in basic science perspective
Kwon, H. N., Oh, S., Jin, X., An, Y., & Park, S. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0552-4 · Cited by 32
Gravenmier, C. A., Siddique, M., & Gatenby, R. A. (2017) · Bulletin of Mathematical Biology · doi:10.1007/s11538-017-0261-x · Cited by 30
Curative role of pantothenic acid in brain damage of gamma irradiated rats
Shedid, S. M., Saada, H. N., Na, E., & Hammad, A. (2017) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-017-0683-0 · Cited by 30
Ikota, H., Nobusawa, S., Arai, H., Kato, Y., Ishizawa, K., Hirose, T., & Yokoo, H. (2015) · Brain Tumor Pathology · doi:10.1007/s10014-015-0222-8 · Cited by 30
2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies
Raimondi, V., Ciotti, G., Gottardi, M., & Ciccarese, F. (2022) · Biomedicines · doi:10.3390/biomedicines10061359 · Cited by 35
Genetic alterations in chondrosarcomas – keys to targeted therapies?
Samuel, A. M., Costa, J. C., & Lindskog, D. M. (2014) · Cellular Oncology · doi:10.1007/s13402-014-0166-8 · Cited by 35
Takahashi, Y., Nakamura, H., Makino, K., Hide, T., Muta, D., Kamada, H., & Kuratsu, J. (2013) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-11-284 · Cited by 30
WANG, G., Sai, K., Gong, F., Yang, Q., Chen, F., & Lin, J. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2052 · Cited by 29
Lee, D., Suh, Y., Kang, S. Y., Park, T. I., Jeong, J. Y., & Kim, S. H. (2012) · Brain Pathology · doi:10.1111/bpa.12000 · Cited by 30
Contemporary murine models in preclinical astrocytoma drug development
McNeill, R. S., Vitucci, M., Wu, J., & Miller, C. R. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou288 · Cited by 31
Enigmas of IDH mutations in hematology/oncology
Heuser, M., Cruz, M. M. A., Goparaju, R., & Chaturvedi, A. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.005 · Cited by 28
IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53
Jiang, B., Zhao, W., Shi, M., Zhang, J., Chen, A., Ma, H., Suleman, M., Lin, F., Zhou, L., Wang, J., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001385 · Cited by 29
Lemasters, J. J. (2021) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2021.148410 · Cited by 31
Oligodendroglioma: A Review of Management and Pathways
Zerdan, M. B., & Assi, H. I. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.722396 · Cited by 30
Pheochromocytoma: Gasping for Air
Jochmanová, I., Zhuang, Z., & Pacák, K. (2015) · Hormones and Cancer · doi:10.1007/s12672-015-0231-4 · Cited by 30
Brooks, E. E., Wu, X., Hanel, A., Nguyen, S., Wang, J., Zhang, J. H., Harrison, A., & Zhang, W. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114541148 · Cited by 29
Watching tumours gasp and die with MRI: the promise of hyperpolarised13C MR spectroscopic imaging
Brindle, K. M. (2012) · British Journal of Radiology · doi:10.1259/bjr/81120511 · Cited by 29
IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients
Chen, N., Yu, T., Gong, J., Nie, L., Chen, X., Zhang, M., Xu, M., Tan, J., Su, Z., Zhong, J., et al. (2016) · Pathology · doi:10.1016/j.pathol.2016.07.010 · Cited by 29
Hyperbaric oxygen therapy as adjunctive strategy in treatment of glioblastoma multiforme
Huang, L., Boling, W., & Zhang, J. H. (2018) · Medical Gas Research · doi:10.4103/2045-9912.229600 · Cited by 29
Lewandowska, M. A., Furtak, J., Szylberg, T., Roszkowski, K., Windorbska, W., Rytlewska, J., & Jóźwicki, W. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0050-7 · Cited by 28
Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: A phantom study
Bertolino, N., Marchionni, C., Ghielmetti, F., Burns, B. L., Finocchiaro, G., Anghileri, E., Bruzzone, M. G., & Minati, L. (2014) · Physica Medica · doi:10.1016/j.ejmp.2014.03.002 · Cited by 28
Photodynamic therapy for glioblastoma: A light at the end of the tunnel
Miretti, M., Graglia, M. A. G., Suárez, A. I., & Prucca, C. G. (2023) · Journal of Photochemistry and Photobiology · doi:10.1016/j.jpap.2023.100161 · Cited by 29
Long non-coding RNA in glioma: novel genetic players in temozolomide resistance
Roh, J., Im, M., Kang, J., Youn, B., & Kim, W. (2023) · Animal Cells and Systems · doi:10.1080/19768354.2023.2175497 · Cited by 28
Oxygen Sensing: A Common Crossroad in Cancer and Neurodegeneration
Quaegebeur, A., & Carmeliet, P. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_83 · Cited by 27
Dehne, N., Hintereder, G., & Brüne, B. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.02.019 · Cited by 28
Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations
Kaneko, M. K., Morita, S., Tsujimoto, Y., Yanagiya, R., Nasu, K., Sasaki, H., Hozumi, Y., Goto, K., Natsume, A., Watanabe, M., et al. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.01.088 · Cited by 27
Should Biomarkers Be Used to Design Personalized Medicine for the Treatment of Glioblastoma?
Weller, M., Wick, W., Hegi, M. E., Stupp, R., & Tabatabai, G. (2010) · Future Oncology · doi:10.2217/fon.10.113 · Cited by 27
Noorden, C. J. F. V., Hira, V. V. V., van Dijck, A. J., Novak, M., Breznik, B., & Molenaar, R. J. (2021) · Cells · doi:10.3390/cells10030705 · Cited by 29
Pappula, A. L., Rasheed, S., Mirzaei, G., Petreaca, R. C., & Bouley, R. A. (2021) · Cancers · doi:10.3390/cancers13174299 · Cited by 27
Blanc‐Durand, P., Gucht, A. V. D., Verger, A., Langen, K., Dunet, V., Bloch, J., Brouland, J., Lalonde, M. N., Schaefer, N. G., & Prior, J. O. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199379 · Cited by 27
The impact of next generation sequencing technologies on haematological research – A review
Black, J. S., Salto‐Tellez, M., Mills, K., & Catherwood, M. A. (2015) · Pathogenesis · doi:10.1016/j.pathog.2015.05.004 · Cited by 27
Yao, L., Barontini, M., Niederle, B., Jech, M., Pfragner, R., & Dahia, P. L. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2245 · Cited by 27
Scutellarin activates IDH1 to exert antitumor effects in hepatocellular carcinoma progression
Cui, Z., Li, C., Liu, W., Sun, M., Deng, S., Cao, J., Yang, H., & Chen, P. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06625-6 · Cited by 29
A system-level approach identifies HIF-2α as a critical regulator of chondrosarcoma progression
Kim, H., Cho, Y., Kim, H. S., Kang, D., Cheon, D., Kim, Y., Chang, M. J., Lee, K. M., Chang, C. B., Kang, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18817-7 · Cited by 31
Kang, X., Chen, R., Zhang, J., Li, G., Dai, P., Chen, C., & Wang, H. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.8.3355 · Cited by 26
Prognostic Value of IDH1 Mutations Identified with PCR-RFLP Assay in Glioblastoma Patients
Bujko, M., Kober, P., Matyja, E., Nauman, P., Dyttus‐Cebulok, K., Czeremszynska, B., Bonicki, W., & SIEDLECKI, J. A. (2010) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256369 · Cited by 26
Polívka, J., Pešta, M., Pitule, P., Hes, O., Holubec, L., Polívka, J., Kubíková, T., & Tonar, Z. (2018) · Oncotarget · doi:10.18632/oncotarget.24536 · Cited by 28
Keßler, J., Hohmann, T., Güttler, A., Petrenko, M., Ostheimer, C., Hohmann, U., Bache, M., Dehghani, F., & Vordermark, D. (2019) · Cancers · doi:10.3390/cancers11060889 · Cited by 28
Garrett-Bakelman, F. E., & Melnick, A. M. (2016) · Epigenomics · doi:10.2217/epi-2016-0008 · Cited by 25
Hypoxia-induced epigenetic regulation of breast cancer progression and the tumour microenvironment
Capatina, A. L., Malcolm, J. R., Stenning, J., Moore, R. L., Bridge, K. S., Brackenbury, W. J., & Holding, A. N. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1421629 · Cited by 31
In Vivo Modeling of Malignant Glioma
Kegelman, T. P., Hu, B., Emdad, L., Das, S. K., Sarkar, D., & Fisher, P. B. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00007-x · Cited by 23
Perizzolo, M., Winkfein, B., Hui, S., Krulicki, W., Chan, J. A.-W., & Demetrick, D. J. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00579.x · Cited by 25
Olar, A., Raghunathan, A., Albarracin, C. T., Aldape, K., Cahill, D. P., Powell, S. Z.-E., Goodman, J. C., & Fuller, G. N. (2011) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2011.08.010 · Cited by 25
Naranjo‐Suarez, S., Carlson, B. A., Tobe, R., Yoo, M., Tsuji, P. A., Gladyshev, V. N., & Hatfield, D. L. (2013) · Molecules and Cells · doi:10.1007/s10059-013-0121-y · Cited by 25
Chotirat, S., Thongnoppakhun, W., Wanachiwanawin, W., & Auewarakul, C. U. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.11.017 · Cited by 25
Patnaik, M. M., Lasho, T. L., Finke, C. M., Knudson, R. A., Ketterling, R. P., Chen, D., Hoyer, J. D., Hanson, C. A., & Tefferi, A. (2011) · American Journal of Hematology · doi:10.1002/ajh.21984 · Cited by 25
Regulation and dysregulation of astrocyte activation and implications in tumor formation
Yang, C.-Z., Rahimpour, S., Yu, A., Lonser, R., & Zhuang, Z. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1274-8 · Cited by 32
Ke, S., Chen, S., Dong, Z., Hong, C. S., Zhang, Q., Tang, L., Yang, P., Zhai, J., Yan, H., Shen, F., et al. (2016) · Hepatology · doi:10.1002/hep.28889 · Cited by 28
Metadata
- Authors
- Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., Ding, J., Lei, Q., Guan, K.-L., & Xiong, Y.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Molecular and Cell Biology Laboratory, Institute of Biomedical Sciences, Fudan University, 130 Dong-An Road, Shanghai 200032, China.
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Lin, Yan
- Xu, Wei
- Jiang, Wenqing
- Guan, Kun-Liang
- Xiong, Yue
- ORCID
- Venue
- Science
- Published
- 2009-04-10
- Volume
- 324
- Issue
- 5924
- Pages
- 261-265
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3251015
- OpenAlex
- W1964150693
- Cited by
- 1,119
- References
- 12
- Citations by year
- 2026: 24 · 2025: 27 · 2024: 43 · 2023: 36 · 2022: 50 · 2021: 62 · 2020: 58 · 2019: 54 · 2018: 63 · 2017: 71 · 2016: 57 · 2015: 71 · 2014: 74 · 2013: 90 · 2012: 84
- FWCI
- 37.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA068377)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH1 mutation, isocitrate dehydrogenase, glioma, HIF-1α, alpha-ketoglutarate, heterodimer formation, tumor suppressor, hypoxia, carcinogenesis, brain tumors, enzyme activity
- MeSH terms
- Adolescent, Adult, Aged, Astrocytoma, Brain Neoplasms, Cell Line, Child, Female, Glioblastoma, Glioma, Humans, Isocitrate Dehydrogenase, Ketoglutaric Acids, Male, Middle Aged, Oligodendroglioma, Oxalates, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Mutant Proteins, Hypoxia-Inducible Factor 1, alpha Subunit, Biocatalysis, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
